• Mr. Isaiah Genga assembling our Partec Microscope at Homabay, Kenya.

    Mr. Isaiah Genga assembling our Partec Microscope at Homabay, Kenya.

  • Kheri Vincent processes samples at the EMBLEM laboratory in Bugando Medical Centre.

    Kheri Vincent processes samples at the EMBLEM laboratory in Bugando Medical Centre.

  • EMBLEM vehicle during field work.

    EMBLEM vehicle during field work.

  • EMBLEM research assisting conducing census in northern Uganda.

    EMBLEM research assisting conducing census in northern Uganda.

  • EMBLEM team meets a local council one executive to explain about the study.

    EMBLEM team meets a local council one executive to explain about the study.

  • Dr. Martin Ogwang officially launching EMBLEM activities in Kuluva Hospital.

    Dr. Martin Ogwang officially launching EMBLEM activities in Kuluva Hospital.

  • Dr. Sam Mbulaiteye training local staff in household census forms.

    Dr. Sam Mbulaiteye training local staff in household census forms.

  • A local woman carrying water back home in the EMBLEM study area in northern Uganda.

    A local woman carrying water back home in the EMBLEM study area in northern Uganda.

  • Members of the EMBLEM Northwest Community Advisory Board and EMBLEM PIs at a meeting in Nebbi, Uganda.

    Members of the EMBLEM Northwest Community Advisory Board and EMBLEM PIs at a meeting in Nebbi, Uganda.

The National Cancer Institute (NCI) is conducting a multicountry and multiyear case-control study of childhood Burkitt’s lymphoma in Uganda, Tanzania and Kenya. The study, entitled Epidemiology of Burkitt’s Lymphoma in East-African Children and Minors (EMBLEM), will evaluate the role of:

  1. Repeated malaria infections in endemic Burkitt’s lymphoma,
  2. Malaria genetic variants in Burkitt’s lymphoma,
  3. Epstein-Barr virus (EBV) genetic variants in Burkitt’s lymphoma.

The specific hypotheses that will be tested are, whether:

  • Carriage of genetic markers that increase resistance to malaria is associated with decreased risk of Burkitt’s lymphoma.
  • Certain EBV genetic variants are associated with increased risk for Burkitt’s lymphoma.

In addition, the study will generate a unique data and sample repository to allow for novel study exploration into the etiology and biology of the disease, including the use of genome-wide scans.

To learn more about EMBLEM and Burkitt lymphoma, watch our video.